{"id":"NCT03340064","sponsor":"UCB Japan Co. Ltd.","briefTitle":"A Study of Levetiracetam as Monotherapy or Adjunctive Treatment of Partial Seizures in Pediatric Epileptic Subjects Ranging From 1 Month to Less Than 4 Years of Age","officialTitle":"An Open-Label, Single-Arm, Multicenter Study of Levetiracetam as Monotherapy or Adjunctive Treatment of Partial Seizures in Pediatric Epileptic Subjects Ranging From 1 Month to Less Than 4 Years of Age","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-11-30","primaryCompletion":"2021-06-01","completion":"2023-07-28","firstPosted":"2017-11-13","resultsPosted":"2024-07-23","lastUpdate":"2024-07-23"},"enrollment":38,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Partial Seizures"],"interventions":[{"type":"DRUG","name":"Levetiracetam","otherNames":["Keppra","E-Keppra","LEV"]}],"arms":[{"label":"Levetiracetam","type":"EXPERIMENTAL"}],"summary":"This is a study to confirm the efficacy of levetiracetam as adjunctive treatment or as monotherapy in pediatric epilepsy subjects aged 1 month to less than 4 years of age with partial seizures.","primaryOutcome":{"measure":"Percent Change in Partial Seizure Frequency Per Week From Baseline to Visit 6","timeFrame":"From Baseline (Week 0) to Visit 6 (up to Week 6)","effectByArm":[{"arm":"Levetiracetam: Adjunctive Therapy","deltaMin":24.24,"sd":null}],"pValues":[]},"eligibility":{"minAge":"1 Month","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":18},"locations":{"siteCount":21,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":18,"n":32},"commonTop":["Nasopharyngitis","Pyrexia","Eczema","Gastroenteritis","Diarrhoea"]}}